Caisse de depot et placement du Quebec Makes New $25.81 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Caisse de depot et placement du Quebec purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 85,748 shares of the biopharmaceutical company’s stock, valued at approximately $25,813,000.

Several other large investors have also modified their holdings of the business. MV Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $25,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $27,000. Golden State Wealth Management LLC increased its position in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $29,000. Finally, Manchester Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 72 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 0.2%

ALNY opened at $237.10 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The business has a 50-day moving average of $262.62 and a two-hundred day moving average of $293.73. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The stock has a market capitalization of $31.73 billion, a price-to-earnings ratio of 44.07 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period in the prior year, the firm posted ($0.51) EPS. The company’s revenue was up 66.9% on a year-over-year basis. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Weiss Ratings raised Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. Royal Bank Of Canada cut their target price on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Needham & Company LLC reduced their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Stifel Nicolaus decreased their price target on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Finally, Bank of America cut their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $386.14.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.